Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 832


Limited Role of Promoter Methylation of <i>MGMT</i> and <i>C13ORF18</i> in Triage of Low-Grade Squamous Intraepithelial Lesion.

Sun LL, Liu Y, Sun X, Pan L, Wu D, Wang YD.

Chin Med J (Engl). 2018 Apr 20;131(8):939-944. doi: 10.4103/0366-6999.229896.


Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.

Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY, Min KW.

Pathol Res Pract. 2018 Apr 5. pii: S0344-0338(18)30181-X. doi: 10.1016/j.prp.2018.04.002. [Epub ahead of print]


Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.

Gessler F, Bernstock JD, Braczynski A, Lescher S, Baumgarten P, Harter PN, Mittelbronn M, Wu T, Seifert V, Senft C.

Neurosurgery. 2018 Mar 27. doi: 10.1093/neuros/nyy049. [Epub ahead of print]


Trps1 is associated with the multidrug resistance of lung cancer cell by regulating MGMT gene expression.

Liu H, Liao Y, Tang M, Wu T, Tan D, Zhang S, Wang H.

Cancer Med. 2018 Mar 30. doi: 10.1002/cam4.1421. [Epub ahead of print]


PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.

Fulton B, Short SC, James A, Nowicki S, McBain C, Jefferies S, Kelly C, Stobo J, Morris A, Williamson A, Chalmers AJ.

Clin Transl Radiat Oncol. 2017 Nov 21;8:12-16. doi: 10.1016/j.ctro.2017.11.003. eCollection 2018 Jan.


Effects of Some Growth Factors and Cytokines on the Expression of the Repair Enzyme MGMT and Protein MARP in Human Cells In Vitro : Effect of Some Growth Factors and Cytokines.

Kotsarenko K, Lylo V, Ruban T, Macewicz L, Lukash L.

Biochem Genet. 2018 Mar 27. doi: 10.1007/s10528-018-9854-9. [Epub ahead of print]


Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.

Li ZC, Bai H, Sun Q, Li Q, Liu L, Zou Y, Chen Y, Liang C, Zheng H.

Eur Radiol. 2018 Mar 21. doi: 10.1007/s00330-017-5302-1. [Epub ahead of print]


Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients.

Chen YY, Ho HL, Lin SC, Ho TD, Hsu CY.

Am J Clin Pathol. 2018 Mar 29;149(5):412-417. doi: 10.1093/ajcp/aqy008.


MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme.

Gurrieri L, De Carlo E, Gerratana L, De Maglio G, Macerelli M, Pisa FE, Masiero E, Aprile G, Follador A, Puglisi F, Fasola G, Rizzato S, Pizzolitto S.

Future Oncol. 2018 Apr;14(8):699-707. doi: 10.2217/fon-2017-0437. Epub 2018 Mar 9.


MGMT promoter methylation in Peruvian patients with glioblastoma.

Belmar-Lopez C, Castaneda CA, Castillo M, García-Corrochano P, Orrego E, Meléndez B, Casavilca S, Flores C, Orrego E.

Ecancermedicalscience. 2018 Feb 14;12:812. doi: 10.3332/ecancer.2018.812. eCollection 2018.


S-phase Specific Downregulation of Human O<sup>6</sup>-Methylguanine DNA Methyltransferase (MGMT) and its Serendipitous Interactions with PCNA and p21<sup>cip1</sup> Proteins in Glioma Cells.

Mostofa A, Punganuru SR, Madala HR, Srivenugopal KS.

Neoplasia. 2018 Apr;20(4):305-323. doi: 10.1016/j.neo.2018.01.010. Epub 2018 Mar 3.


The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.

Lee A, Youssef I, Osborn VW, Safdieh J, Becker DJ, Schreiber D.

J Clin Neurosci. 2018 May;51:85-90. doi: 10.1016/j.jocn.2018.02.009. Epub 2018 Feb 23.


Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.

Han Y, Yan LF, Wang XB, Sun YZ, Zhang X, Liu ZC, Nan HY, Hu YC, Yang Y, Zhang J, Yu Y, Sun Q, Tian Q, Hu B, Xiao G, Wang W, Cui GB.

BMC Cancer. 2018 Feb 21;18(1):215. doi: 10.1186/s12885-018-4114-2.


Promoter methylation of <i>RB1</i>, <i>P15</i>, <i>P16</i>, and <i>MGMT</i> and their impact on the clinical course of pilocytic astrocytomas.

Sippl C, Urbschat S, Kim YJ, Senger S, Oertel J, Ketter R.

Oncol Lett. 2018 Feb;15(2):1600-1606. doi: 10.3892/ol.2017.7490. Epub 2017 Nov 24.


Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?

Pala A, Schmitz AL, Knoll A, Schneider M, Hlavac M, König R, Wirtz CR, Coburger J.

Clin Neurol Neurosurg. 2018 Apr;167:6-10. doi: 10.1016/j.clineuro.2018.02.003. Epub 2018 Feb 5.


Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.

Kramer B, Singh R, Wischusen J, Dent R, Rush A, Middlemiss S, Ching YW, Alexander IE, McCowage G.

Hum Gene Ther. 2018 Mar 23. doi: 10.1089/hum.2017.235. [Epub ahead of print]


The role of MGMT polymorphisms rs12917 and rs11016879 in head and neck cancer risk and prognosis.

Kiczmer P, Prawdzic Seńkowska A, Strzelczyk JK, Szydło B, Biernacki K, Osadnik T, Krakowczyk Ł, Ostrowska Z.

Acta Biochim Pol. 2018;65(1):87-92. doi: 10.18388/abp.2017_1613. Epub 2018 Jan 25.


A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma.

Chen L, Wang Y, Liu F, Xu L, Peng F, Zhao N, Fu B, Zhu Z, Shi Y, Liu J, Wu R, Wang C, Yao S, Li Y.

Sci Rep. 2018 Jan 23;8(1):1439. doi: 10.1038/s41598-018-19949-z.


MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.

Micko ASG, Höftberger R, Wöhrer A, Millesi M, Knosp E, Wolfsberger S.

Pituitary. 2018 Jan 17. doi: 10.1007/s11102-018-0862-x. [Epub ahead of print]


Temozolomide analog PMX 465 downregulates MGMT expression in HCT116 colorectal carcinoma cells.

Yang Z, Wei D, Liu F, Liu J, Wu X, Stevens MFG, Bradshaw TD, Luo Y, Zhang J.

J Cell Biochem. 2018 Jan 13. doi: 10.1002/jcb.26674. [Epub ahead of print]


Supplemental Content

Support Center